CW Advisors LLC Has $31.09 Million Position in Boston Scientific Corporation $BSX

CW Advisors LLC lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 19.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 289,421 shares of the medical equipment provider’s stock after purchasing an additional 48,132 shares during the period. CW Advisors LLC’s holdings in Boston Scientific were worth $31,087,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific during the first quarter worth approximately $27,000. Sound Income Strategies LLC grew its stake in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Princeton Global Asset Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific in the 2nd quarter worth approximately $37,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research report on Friday, October 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a report on Thursday, October 23rd. The Goldman Sachs Group reissued a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, October 22nd. Robert W. Baird raised their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Finally, Truist Financial boosted their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $123.77.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 143,095 shares of company stock valued at $14,228,950. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Down 2.0%

NYSE:BSX opened at $99.03 on Wednesday. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The stock has a 50-day moving average price of $99.28 and a two-hundred day moving average price of $102.19. The stock has a market cap of $146.80 billion, a price-to-earnings ratio of 52.96, a PEG ratio of 2.03 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the business posted $0.63 EPS. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.